Overview
CMPX market data
Price History
CMPX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.42 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.87 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -5,808.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.61 – $6.88 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $399.8M · P/B 4.85.
Company News
Compass Therapeutics shares are trading higher after Piper Sandler raised its price target on the stock from $4 to $6.Benzinga · Aug 7, 2026, 6:28 PM
Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6Benzinga · Aug 7, 2026, 4:58 PM
Compass Therapeutics Q2 EPS $(0.13) Misses $(0.11) EstimateBenzinga · Aug 6, 2026, 11:56 AM
8-K filing — Compass Therapeutics, Inc. (CMPX)SEC EDGAR · Aug 6, 2026, 11:30 AM
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026Globenewswire Inc · Jul 17, 2026, 3:15 PM
Compass Therapeutics Abstract Accepted For Oral Presentation At Upcoming European Society For Medical Oncology CongressBenzinga · Jul 17, 2026, 2:47 PM
Compass Therapeutics' CTX-8371 Dual PD-1/PD-L1 Bispecific Shows Durable Monotherapy Responses In Advanced Checkpoint-Resistant Cancers With Favorable Safety ProfileBenzinga · May 21, 2026, 9:15 PM
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual MeetingGlobenewswire Inc · May 21, 2026, 9:15 PM